viewModerna Therapeutics Inc

Coronavirus: UK approves Moderna vaccine and to impose negative test for travellers, BioNTech/Pfizer jab may work against new strain

Because of Brexit, the UK is not expected to receive the first Moderna deliveries until April

Moderna Therapeutics Inc - Coronavirus: UK to impose negative test for travellers and to approve Moderna vaccine, BioNTech/Pfizer jab may against new strain

In coronavirus news this Friday, the UK has approved the vaccine developed by Moderna Therapeutics Inc (NASDAQ:MRNA) but because of Brexit deliveries will not arrive before April.

London has ordered 7mln doses of the jab, already approved in the EU, which has secured 160mln doses, and the US.

According to an analysis carried out for the Guardian, vaccinations need to double each week over the next fortnight to reach the government’s target to immunize all 13.9mln vulnerable people by mid-February.

The Moderna vaccine, the third approved in the UK, will not help towards this goal.

So far, 1.3mln people in the UK have received the first dose of the BioNTech/Pfizer Inc (NYSE:PFI) or the Oxford/AstraZeneca PLC (LON:AZN) jabs and 21,000 the booster dose.

Mandatory negative tests at the border

England and Scotland have joined many other countries in requiring a negative COVID-19 test result for inbound travellers.

All international arrivals, including UK nationals, will be required to take the assay up to 72 hours prior to departure.

Passengers be subject to an immediate fine of £500 if they fail to comply, while the 10-day quarantine is still mandatory unless people are coming from countries on the government’s travel corridor list.

England will implement the measure as early as next week.

Good for variation

The BioNTech/Pfizer inoculation may be effective against the new virus variants found in the UK and South Africa, according to a study by the University of Texas Medical Branch and supported by the two companies.

Researchers tested antibodies in the blood of people who received the jab against a lab-created version of the new strain.

--Adds Moderna vaccine approval news--

Quick facts: Moderna Therapeutics Inc

Price: 129.65 USD

Market: NASDAQ
Market Cap: $51.3 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Alpha Growth's BlackOak Alpha Growth Fund generates positive returns despite...

Alpha Growth PLC (LON:ALGW) (OTCQB: ALPGF) CEO Gobind Sahney tells Proactive the financial services specialist's BlackOak Alpha Growth Fund produced a 2020 calendar year return of 10.63% and a 13.71% total return since inception in September 2019. Sahney says given the challenges of 2020, its...

14 hours, 27 minutes ago

2 min read